BriaCell Therapeutics Corp. announces the appointment of Giuseppe Del Priore, MD, MPH, as the Company's Chief Medical Officer, effective February 16, 2022. Dr. Del Priore will oversee the clinical and regulatory aspects of BriaCell's current and upcoming clinical trials including the ongoing Phase I/IIa combination study of BriaCell's lead candidate, Bria-IMT, with Incyte's checkpoint inhibitors, retifanlimab and epacadostat in advanced breast cancer.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.29 CAD | +7.01% | +16.24% | -70.64% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-70.64% | 3.07Cr | |
+11.91% | 12TCr | |
+11.60% | 11TCr | |
-4.68% | 2.43TCr | |
-0.82% | 2.2TCr | |
-10.12% | 1.82TCr | |
-42.12% | 1.64TCr | |
-17.47% | 1.56TCr | |
+2.77% | 1.36TCr | |
+34.58% | 1.23TCr |
- Stock Market
- Equities
- BCT Stock
- News BriaCell Therapeutics Corp.
- Briacell Therapeutics Corp. Appoints Giuseppe Del Priore as Chief Medical Officer